Thermo Fisher Scientific, Alnylam Pharmaceuticals, AbbVie, Vertex Pharmaceuticals, and Danaher are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that research, develop and commercialize products derived from living organisms—such as drugs, vaccines, gene therapies and diagnostic tools. Because their fortunes hinge on scientific breakthroughs, clinical‐trial outcomes and regulatory approvals, these stocks often exhibit higher volatility and the potential for outsized gains or losses. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
NYSE:TMO traded up $0.98 during mid-day trading on Monday, hitting $464.02. 742,999 shares of the company traded hands, compared to its average volume of 2,519,366. The firm has a market cap of $175.16 billion, a price-to-earnings ratio of 26.84, a price-to-earnings-growth ratio of 2.47 and a beta of 0.74. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock's fifty day moving average price is $420.88 and its 200-day moving average price is $466.41. Thermo Fisher Scientific has a one year low of $385.46 and a one year high of $627.88.
Read Our Latest Research Report on TMO
Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Alnylam Pharmaceuticals stock traded up $15.87 during midday trading on Monday, reaching $417.67. 662,134 shares of the stock traded hands, compared to its average volume of 924,867. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $417.87. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. The stock's fifty day moving average is $318.24 and its 200-day moving average is $279.01. The stock has a market cap of $54.75 billion, a P/E ratio of -169.10 and a beta of 0.25.
Read Our Latest Research Report on ALNY
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of NYSE ABBV traded up $0.51 during midday trading on Monday, hitting $195.73. The company's stock had a trading volume of 1,394,187 shares, compared to its average volume of 6,839,041. AbbVie has a 12-month low of $163.81 and a 12-month high of $218.66. The firm has a market cap of $345.74 billion, a P/E ratio of 93.15, a price-to-earnings-growth ratio of 1.27 and a beta of 0.50. The business's 50 day moving average is $188.33 and its two-hundred day moving average is $190.42. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14.
Read Our Latest Research Report on ABBV
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of Vertex Pharmaceuticals stock traded up $5.61 during trading on Monday, reaching $467.74. The company's stock had a trading volume of 470,459 shares, compared to its average volume of 1,513,580. The company has a 50-day simple moving average of $455.62 and a two-hundred day simple moving average of $467.10. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a quick ratio of 2.29, a current ratio of 2.65 and a debt-to-equity ratio of 0.01. The company has a market cap of $120.11 billion, a price-to-earnings ratio of -119.34 and a beta of 0.44.
Read Our Latest Research Report on VRTX
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Shares of Danaher stock traded down $0.16 on Monday, hitting $196.93. The company's stock had a trading volume of 1,063,845 shares, compared to its average volume of 4,292,571. Danaher has a 1 year low of $171.00 and a 1 year high of $279.90. The firm has a fifty day moving average price of $197.49 and a 200-day moving average price of $202.16. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The company has a market capitalization of $141.01 billion, a price-to-earnings ratio of 41.90, a price-to-earnings-growth ratio of 2.74 and a beta of 0.73.
Read Our Latest Research Report on DHR
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
